• Oral REVLIMID® is the first and only medicine licensed in Europe for use as post-autologous stem cell trans­plan­ta­tion main­te­nance ther­apy in multiple myeloma
• The new indi­ca­tion expands the avail­a­bil­ity of REVLIMID® across the disease con­tin­uum of multiple myeloma

Boudry, Switzerland (Press Release) – Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ: CELG), today announced that the European Com­mis­sion (EC) has approved REVLIMID® (lena­lido­mide) as mono­therapy for the main­te­nance treat­ment of adult patients with newly diag­nosed multiple myeloma who have undergone au­tol­o­gous stem cell trans­plan­ta­tion (ASCT). REVLIMID® is the first and only licensed main­te­nance treat­ment avail­able to these patients.

The REVLIMID® Marketing Authorisation has been updated to in­clude this new indi­ca­tion, which expands on the existing multiple myeloma indi­ca­tions as …

• REVLIMID is the first and only treat­ment approved for main­te­nance fol­low­ing auto-HSCT
• Updated data from two large, ran­domized, controlled studies dem­onstrated median pro­gres­sion-free survival (PFS) advantages of 3.8 and 1.9 years, re­spec­tive­ly, in favor of patients receiving REVLIMID compared to no main­te­nance
• Median over­all survival (OS) for patients receiving REVLIMID in each study was 9.3 years and 8.8 years, re­spec­tive­ly, compared to 7 and 7.3 years for no main­te­nance in a descriptive analysis (studies not powered for OS)
• Approval enables Celgene to provide patients with treat­ment options across the multiple myeloma spectrum

Summit, NJ (Press Release) – Celgene Corpo­ra­tion (NASDAQ:CELG) today announced that the U.S. Food and Drug Admin­istra­tion (FDA) has expanded the existing indi­ca­tion for REVLIMID (lena­lido­mide) 10 mg capsules to in­clude use for patients with multiple myeloma as main­te­nance ther­apy fol­low­ing au­tol­o­gous hema­to­poietic stem cell trans­plant (auto-HSCT). The expanded indi­ca­tion makes REVLIMID the first and only treat­ment to receive FDA approval for main­te­nance use fol­low­ing auto-HSCT.

“Autologous stem cell trans­plant after induction ther­apy is …

During my 25-year career as a boy’s head basketball coach, I found the most satisfying (and most important) part of coaching was planning and devising game plans. 

Putting my knowledge and experience to test to give my teams the best chance of winning was challenging and time consuming, but also enjoyable and exciting. Equally enjoyable and exciting was making adjustments to the game plan during the course of the game.

At times the game plan worked to perfection. Sometimes, the plan had to be adjusted immediately. With my better teams, the game plans varied …

• REVLIMID® is the first and only medicine granted positive CHMP opinion for post-Autologous Stem Cell Transplantation (ASCT) main­te­nance ther­apy in MM
• The new indi­ca­tion expands the avail­a­bil­ity of REVLIMID® across the disease con­tin­uum of MM

Boudry, Switzerland (Press Release) – Celgene Inter­na­tional Sàrl, a wholly owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of REVLIMID® as mono­therapy for the main­te­nance treat­ment of adult patients with newly diag­nosed multiple myeloma (MM) who have undergone au­tol­o­gous stem cell trans­plan­ta­tion (ASCT). Once approved by the European Com­mis­sion, REVLIMID® will be the first and only licensed main­te­nance treat­ment avail­able to …

I have been off treatment for my multiple myeloma for about six months, so I thought this would be a good time to evaluate where things stand.

First, a short recap for those who have not followed my story.

I was diagnosed with multiple myeloma at the end of June in 2013. Almost immediately, I began what turned out to be six cycles of Velcade (bor­tezo­mib), Revlimid (lenalidomide), and dexa­metha­sone (Decadron). This reg­i­men put me into what appeared to be complete remission. I phrase it that …

This year’s American Society of Clinical Oncology (ASCO) annual meeting began the morning of last Friday, and the meeting will run through Tues­day.

Multiple myeloma-related pre­sen­ta­tions are taking place every day of the meeting. Friday, how­ever, was the busiest day at the meeting in terms of oral pre­sen­ta­tions with new myeloma-related re­search. There were nine such pre­sen­ta­tions during a single afternoon session focused on multiple myeloma.

In addi­tion, there were myeloma-related education session pre­sen­ta­tions on Saturday, yesterday, and today. There also was a late-breaking ab­stract session yesterday (Sunday) with one pre­sen­ta­tion that …

I just returned from a long trip to Europe, and boy do I feel refreshed! The reason I think I feel so good is that I took a holiday not just from work and the mundane problems of home, but I also took a holiday from my multiple myeloma.

I once again find myself feeling guilty for being one of the healthiest guys in the myeloma ward, so let me explain.

My wife and I spent about three weeks in Switzerland and Italy without the kids. It was a great trip. I …